Does high DHT with high DHEA-S suggest increased downstream androgen activation?

DHT biology supports the core biochemical premise: testosterone is converted to DHT by 5-alpha-reductase, and adrenal precursors can fuel local DHT production. The interpretation of simultaneous serum DHT and DHEA-S elevations, however, remains suggestive rather than diagnostic.

Established pathways

• 5-alpha-reductase (SRD5A1 and SRD5A2) catalyzes the NADPH-dependent, effectively irreversible conversion of testosterone to DHT. Human SRD5A2 deficiency produces low DHT and an increased testosterone:DHT ratio, providing in-vivo confirmation.
• These isoenzymes are expressed in peripheral androgen-responsive sites including prostate, skin/scalp, and liver. DHT generated locally activates the androgen receptor.

Peripheral adrenal-androgen activation

• DHEA-S is an adrenal prohormone that can be desulfated by steroid sulfatase and converted through HSD3B, AKR1C3, and 5-alpha-reductase pathways to DHT.
• Direct ex-vivo human prostate and prostate-cancer evidence demonstrates DHEAS-to-DHT conversion. A route through DHEA, androstenedione, and 5α-androstanedione can generate DHT while partly bypassing testosterone; earlier estimates suggest adrenal precursors may contribute up to approximately one-sixth of intraprostatic DHT.
• This local intracrine production is tissue-specific: it is best established in prostate, plausible in skin, and may be limited by rapid DHT inactivation in adipose tissue.

Interpretation and clinical implications

• Concurrent high DHT and DHEA-S plausibly indicates greater downstream androgen availability, including local androgen-receptor activation, but does not measure tissue DHT production or receptor signaling directly.
• DHEA-S and serum DHT need not rise together: controlled DHEA administration increased DHT-conjugated metabolites without materially increasing circulating testosterone or DHT.
• Unexpected results merit confirmation by LC-MS/MS and interpretation alongside testosterone, androstenedione, SHBG, LH/FSH, and medication or supplement exposure. Marked DHEA-S elevation may require assessment for adrenal androgen excess, including adrenal tumor or nonclassic congenital adrenal hyperplasia.

Bottom line

• The biochemical pathways are well established; the combined laboratory pattern is a biologically credible clue to increased androgen activation, but serum values alone cannot establish its magnitude, tissue source, or cause.